Title |
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
|
---|---|
Published in |
Molecular Cancer Therapeutics, August 2017
|
DOI | 10.1158/1535-7163.mct-16-0889 |
Pubmed ID | |
Authors |
Maximilien Murone, Ramin Radpour, Antoine Attinger, Anne Vaslin Chessex, Anne-Laure Huguenin, Christian M Schürch, Yara Banz, Saumitra Sengupta, Michel Aguet, Stefania Rigotti, Yogeshwar Bachhav, Frédéric Massière, Murali Ramachandra, Andres McAllister, Carsten Riether |
Abstract |
Acute myelogenous leukemia (AML) is initiated and maintained by leukemia stem cells (LSCs). LSCs are therapy-resistant, cause relapse and represent a major obstacle for the cure of AML. Resistance to therapy is often mediated by aberrant tyrosine kinase (TK) activation. These TKs primarily activate downstream signaling via STAT3/STAT5. In this study, we analyzed the potential to therapeutically target aberrant TK signaling and to eliminate LSCs via the multi-TK inhibitor Debio 0617B. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL and class III/V receptor TKs. We demonstrate that expression of phospho-STAT3 (pSTAT3) in AML blasts is an independent prognostic factor for overall survival. Furthermore, phospho-STAT5 (pSTAT5) signaling is increased in primary CD34(+) AML stem/progenitors. STAT3/STAT5 activation depends on tyrosine phosphorylation, mediated by several upstream TKs. Inhibition of single upstream TKs did not eliminate LSCs. In contrast, the multi-TK inhibitor Debio 0617B reduced maintenance and self-renewal of primary human AML CD34(+) stem/progenitor cells in vitro and in xenotransplantation experiments resulting in long-term elimination of human LSCs and leukemia. Therefore, inhibition of multiple TKs upstream of STAT3/5 may result in sustained therapeutic efficacy of targeted therapy in AML and prevent relapses. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 19% |
Student > Bachelor | 1 | 6% |
Professor | 1 | 6% |
Lecturer > Senior Lecturer | 1 | 6% |
Student > Ph. D. Student | 1 | 6% |
Other | 3 | 19% |
Unknown | 6 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 25% |
Immunology and Microbiology | 3 | 19% |
Biochemistry, Genetics and Molecular Biology | 1 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
Engineering | 1 | 6% |
Other | 0 | 0% |
Unknown | 6 | 38% |